MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/13506129.2022.2118043

Медицинская библиотека · Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2022

Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.

Quan Dianna, Obici Laura, Berk John L, Ando Yukio, Aldinc Emre, White Matthew T, Adams David

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

Assess how baseline polyneuropathy severity impacts response to patisiran regarding neurologic impairment and quality of life (QOL) in patients with hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis).

METHODS

This post hoc analysis grouped patients from the Phase 3 APOLLO study (n = 225) by baseline Neuropathy Impairment Score (NIS) into quartiles: 6-<31; 31-<57; 57-<85.5; 85.5-141.6. Neurologic impairment (modified NIS+7 [mNIS+7], NIS total score), disability (Rasch-built Overall Disability Scale [R-ODS]), gait speed (10-meter walk test [10-MWT]), grip strength, and QOL (Norfolk Quality of Life-Diabetic Neuropathy [Norfolk QOL-DN] questionnaire) were assessed.

RESULTS

Across all baseline NIS quartiles, patisiran improved several clinical markers of disease compared with placebo at 18 months. Patients in lower NIS quartiles, treated with patisiran earlier in the disease course, maintained better scores in mNIS+7, NIS total score, R-ODS, 10-MWT, grip strength, and Norfolk QOL-DN versus those in higher NIS quartiles, while placebo-treated patients experienced worsening of all functional measures after 18 months across all quartiles.

CONCLUSIONS

Patisiran treatment improved neurologic function and QOL across a wide range of baseline polyneuropathy severities versus placebo. Timing of treatment initiation in patients with ATTRv amyloidosis remains critical for the preservation of function.(ClinicalTrials.gov number, NCT01960348).

Для цитирования: Quan Dianna, Obici Laura, Berk John L, Ando Yukio, Aldinc Emre, White Matthew T, Adams David. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2022. DOI: 10.1080/13506129.2022.2118043.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.